Showing results (11-20 of 1,608) with videos related to
Sort By:
Pageof 161
F1000Research|May 10, 2019
RANKL is a therapeutic target of bone destruction in rheumatoid arthritisSakae TanakaClinical Calcium|March 19, 2005
[Therapeutic vaccination approach against pathological bone disease]Sakae TanakaNihon Rinsho. Japanese Journal of Clinical Medicine|September 16, 2006
[Bone disease related to rheumatoid arthritis]Sakae TanakaEFORT Open Reviews|May 7, 2019
Molecular understanding of pharmacological treatment of osteoporosisSakae TanakaClinical Calcium|April 4, 2007
[RANKL as a target molecule for treatment of joint destruction]Sakae TanakaAmerican Journal of Nephrology|July 27, 2007
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG systemSakae TanakaJBMR Plus|April 18, 2022
Transcription Factor Hematopoietically Expressed Homeobox Protein (Hhex) Negatively Regulates Osteoclast Differentiation by Controlling Cyclin-Dependent Kinase InhibitorsHisato Watanabe, Hiroyuki Okada, Jun Hirose, et al.Regenerative Therapy|December 25, 2025
Lubricin maintains temporomandibular joint homeostasis by regulating synovial inflammationSoichiro Negishi, Kazuhiro Shibusaka, Miki Maemura, et al.JBMR Plus|July 22, 2022
Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic TargetsYasunori Omata, Hiroyuki Okada, Steffen Uebe, et al.Clinical Calcium|September 5, 2006
[Current topics in drug therapy aiming at bone resorption]Tetsuro Yasui, Sakae TanakaPageof 161